Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis

Thorax

Volumn 64, Issue 6, 2009, Pages 535-540

  Mainz, J G ^a,g   Naehrlich, L ^b   Schien, M ^a   Kading M ^c   Schiller, I ^a   Mayr, S ^b   Schneider, G ^a   Wiedemann, B ^d   Wiehlmann, L ^e   Cramer, N ^e   Pfister, W ^a   Kahl, B C ^f   Beck, J F ^a   Tummler B ^e  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; MACROLIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL FLORA; BACTERIUM ISOLATE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; INFANT; LAVAGE; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NOSE CAVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM; STAPHYLOCOCCUS AUREUS; UPPER RESPIRATORY TRACT;

EID: 67249139656     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.104711     Document Type: Article

References (34)

1. Cystic Fibrosis Foundation. Patient Registry 2004. Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation, 2005.
2. Kahl BC, Duebbers A, Lubritz G, et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003;41:4424-4427 (Pubitemid 37099721)
3. Cystic Fibrosis Foundation Patient Registry. 2001 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2002.
4. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-161
5. Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-158 (Pubitemid 26127307)
6. Ramsey B, Richardson MA. Impact of sinusitis in cystic fibrosis. J Allergy Clin Immunol 1992;90:547-552
7. Gysin C, Alothman GA, Papsin BC. Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol 2000;30:481-489
8. Coste A, Gilain L, Roger G, et al. Endoscopic and CT-scan evaluation of rhinosinusitis in cystic fibrosis. Rhinology 1995;33:152-156.
9. Eggesbo HB, Sovik S, Dolvik S, et al. CT characterization of developmental variations of the paranasal sinuses in cystic fibrosis. Acta Radiol 2001;42:482-493 (Pubitemid 33655091)
10. Shapiro ED, Milmoe GJ, Wald ER, et al. Bacteriology of the maxillary sinuses in patients with cystic fibrosis. J Infect Dis 1982;146:589-593 (Pubitemid 13250811)
11. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001;17:93-96 (Pubitemid 32103283)
12. Pynnonen MA, Mukerji SS, Kim HM, et al. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg 2007;133:1115-1120 (Pubitemid 350157023)
13. Hogardt M, Häußler S, Balke B, et al. Atemwegsinfektionen bei Mukoviszidose. Mikrobiologisch-infektiologische Qualitätsstandards (MiQ) 24. München, Urban and Fischer, 2006
14. Wiehlmann L, Wagner G, Cramer N, et al. Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2007;104:8101-8106 (Pubitemid 47185882)
15. Kahl BC, Mellmann A, Deiwick S, et al. Variation of the polymorphic region X of the protein A gene during persistent airway infection of cystic fibrosis patients reflects two independent mechanisms of genetic change in Staphylococcus aureus. J Clin Microbiol 2005;43:502-505 (Pubitemid 40096357)
16. Harmsen D, Claus H, Witte W, et al. Typing of methicillin-resistant Staphylococcus aureus in the University hospital setting using a novel software for spa-repeat determination and database management. J Clin Microbiol 2003;41:5442-5448 (Pubitemid 37543228)
17. Kromeyer-Hauschild K, Wabitsch M, Kunze D, et al. Perzentile für den Body-Mass- Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd 2001;149:807-818 (Pubitemid 32830649)
18. Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child 1958;96:6-15.
19. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37:225-264. (Pubitemid 37260463)
20. Kerem E, Corey M, Gold R, et al. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa. J Pediatr 1990;116:714-719. (Pubitemid 20162819)
21. Armstrong D, Cohen J. Infectious diseases. London, UK: Harcourt Publishers, 1999.
22. Muhlebach MS, Miller MB, Moore C, et al. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatric Pulmonology 2006;41:445-451
23. Taylor RF, Morgan DW, Nicholson PS, et al. Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis. Thorax 1992;47:426-428
24. Walter S, Gudowius P, Bosshammer J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 1997;52:318-321 (Pubitemid 27204891)
25. Cimmino M, Cavaliere M, Nardone M, et al. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis. Clin Otolaryngol Allied Sci 2003;28:125-132 (Pubitemid 36514149)
26. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92. (Pubitemid 28110583)
27. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;103:8487-8492 (Pubitemid 43838482)
28. Bush A, Alton EWFW, Davies JC, et al. Cystic fibrosis in the 21st century. Basel, Switzerland: Karger, 2006.
29. Tsang V, Pitt TL, Kaufmann ME, et al. Colonisation of lung allografts with Pseudomonas aeruginosa in heart-lung transplant recipients with cystic fibrosis. Thorax 1994;49:721-722 (Pubitemid 24219156)
30. Batsakis JG, El-Naggar AK. Cystic fibrosis and the sinonasal tract. Ann Otol Rhinol Laryngol 1996;105:329-330 (Pubitemid 26121591)
31. Davidson TM, Murphy C, Mitchell M, et al. Management of chronic sinusitis in cystic fibrosis. Laryngoscope 1995;105:354-358
32. Lewiston N, King V, Umetsu D, et al. Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage. Transplant Proc 1991;23:1207-1208
33. Nunley DR, Grgurich W, Iacono AT, et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998;113:1235-1243 (Pubitemid 28223810)
34. Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cystic Fibrosis 2009;8S:10-14